Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.
Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1664 Market Dynamics Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients. Increasing number of pipeline products is expected to drive growth of the dementia drugs market Major factors fueling growth of the dementia drugs market include the large number of drugs in the pipeline, which are expected to enter into the market by 2020-2022. According to the study published by Translational Research and Clinical Intervention, in September 2017, it is recorded that 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint efforts is also boosting growth of the market. For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease. Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT to boost demand in emerging economies On the basis of geography, the global dementia drugs market can be segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold the largest market, owing to major approval of drugs in this region and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases, especially in China, India. This in turn, is expected to create lucrative opportunities for growth of the market. Some of the top companies operating in the dementia drugs market are Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd. Detailed Segmentation:
For More Information, Browse at https://www.coherentmarketinsights.com/market-insight/dementia-drugs-market-1664 Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected] https://www.coherentmarketinsights.com/phase-xs/ About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
0 Comments
Weight management is an approach to a attaining and maintaining a healthy lifestyle. Weight management includes a healthy balanced diet and physical exercise, to maintain energy intake and energy expenditure. An individual with healthy eating habits can control under-consumption and over-consumption of food. Fad diets that promote fast and temporary weight loss are not included in weight management, rather such management programs focuses on slow weight loss to attain ideal body weight.
Globally, the obese population is increasing, in turn, increasing the incidence of chronic diseases such as musculoskeletal disorders, cardiovascular diseases, hypertension, and diabetes. Treatment of such diseases is highly expensive thus, increasing the demand for weight management programs. According to World Health Organization (WHO) estimation, in 2016, 13% of the world’s adult population was obese, particularly 15% of women and 11% of men population globally. From 1975 to 2016, the prevalence rate of obesity almost tripled. This in turn, is expected to create immense potential for growth of the weight management market. North America held a dominant position in the global weight management market Geographically, North America is expected to hold a dominant position in the market, owing to increasing intake of junk food and improper lifestyle among the populace in the region. Asia Pacific is projected to register highest growth during the forecast period. This growth is primarily attributed to growing awareness of management of body weight to avoid adverse health effects among the populace coupled with emerging medical tourism and healthcare infrastructure in the region. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1057 The weight management market is expected to evolve with the development of novel technologies. For instance, in 2017, Neurovalens raised around US$ 1.6 million in crowdfunding. For the development of Modius, a headband that stimulates the brain to control metabolism and fat storage, boosting the former, while decreasing the individual’s appetite. Furthermore, StayWell acquired MedHelp’s health engagement platform. The acquisition helped the company reach 3 million users of the MedHelp Company and incorporate MedHelp’s Sugar Sense and My Diet Diary apps to its existing diabetes management and weight loss solutions portfolios. The global weight management market is highly fragmented with several companies operating locally. To increase their footprint in the market, major players are adopting strategies such as new product launches, partnerships, acquisitions, and agreements. In October, 2017, EnteroMedics Inc. acquired ReShape Medical Inc. The acquisition added ReShape Medical’s FDA-approved ReShape Dual Weight Loss Balloon, a minimally invasive intragastric balloon to treat obese people. This product will complement EnteroMedical’s weight loss solutions portfolio. Ortho Molecular Products--manufacturer of supplements and nutraceuticals--selected Nattopharma as its exclusive partner for distribution of its Vitamin K2, during the same month. In August, 2017, Europharma Inc.--the producers of Terry Naturally brand of weight management supplement--introduced its new weight loss product Slim-VX1 in the U.S. The product is the end result of blending ginger with VX1, a French grape seed extract. The product was clinically studied in the U.K and showed boost in metabolism, reduction in fat accumulation and body mass index (BMI), along with reduced food cravings, and enhanced feeling of fullness. Some of the key players operating in the global weight management market include Herbalife International Inc., NutriSystem Inc., EnteroMedical Inc., StayWell Inc., Weight Watchers International Inc., Brunswick Corporation, Ethicon US LLC, Ajinomoto Co. Inc., Abbott Nutrition, eDiets.com, Atkins Nutritionals, McNeil Nutritionals, Duke Diet and Fitness Center, Life Time Fitness Inc., Precor Inc., Fitness First Group, and 24 Hours Fitness Click To Reading More On Weight Management Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] Erythromycin is an antibiotic, which is used to treat certain kind of bacterial infections. Erythromycin topical preparations are largely used on the skin to help control acne. The antibiotic is also used in combination with other medicines and are applied topically or taken orally for treating the infections. The common side effects of erythromycin include nausea, loss of appetite, diarrhea, and abdominal pain. Erythromycin prevents bacterial cells from growing and multiplying by interfering with their ability to make proteins, while not affecting human cells. It is widely used to treat chest infections such as pneumonia, skin problems such as acne and rosacea, dental abscesses, and sexually transmitted infections.
Ask For Sample Copy at https://www.coherentmarketinsights.com/insight/request-sample/1780 Erythromycin Market Dynamics Pharmaceutical manufacturers are focused on increasing access to affordable medications to provide novel options for patients and pharmacists, thereby addressing the limited availability of erythromycin tablets, which in turn is expected to augment market growth. For instance, in March, 2018, Amneal Pharmaceuticals received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The erythromycin product is a therapeutic equivalent for the reference listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. Moreover, in September 2016, ANI Pharmaceuticals, Inc. launched Erythromycin Ethylsuccinate for oral suspension 200mg/5mL indicated as a treatment for various infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires disease, pertussis, and others. Erythromycin Market - Regional Dynamics Regional segmentation of the global erythromycin market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America erythromycin market is expected to hold a dominant position over the forecast period, owing to rising number of regulatory approvals of drugs by regulatory agencies to address the unmet medical needs of the patients and increasing prevalence of skin and soft tissue infections. For instance, in November, 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of Valeant International’s Benzamycin Gel, 3-5%. According to the Division of Infectious Diseases, Los Angeles BioMedical Research Center, 2015, skin and soft tissue infections (SSTIs) are a common reason to seek medical care in the U.S. as they can lead to complications with significant morbidity, including hospitalization, surgical procedures, or death. Erythromycin Market- Competitive Analysis Key players operating in the global erythromycin market include Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc. Erythromycin Market Taxonomy: On the basis of formulation, the global erythromycin market is segmented into:
Browse Full Report at https://www.coherentmarketinsights.com/ongoing-insight/erythromycin-market-1780 Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected] https://www.coherentmarketinsights.com/phase-xs/ About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Laser resurfacing, also known as laser peel, laser vaporization or lasabrasion, is used for the treatment of skin problems such as acne scars and facial wrinkles. Laser resurfacing techniques direct short, concentrated beams of light at uneven skin, exactly removing skin layer by layer. The increasing inclination of people towards aesthetic appearance, especially in the urban areas, has resulted in increasing number of laser procedures, which further increases the demand for laser resurfacing devices. Physiology of wrinkled and ageing skin can be improved by aesthetic lasers and energy devices. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, over 11 million aesthetic procedures were performed by board?certified specialists, of which 16.5% were surgical procedures and 83.5% were non?surgical procedures. Laser resurfacing is of two types, namely non-ablative and ablative. Non-ablative laser resurfacing include infrared lasers, fractional laser, high impact light sources, and others. The most commonly used ablative laser resurfacing procedures include erbium laser resurfacing and CO2 laser resurfacing. Changes in lifestyle and increasing incidences related to skin treatment are driving growth of laser resurfacing devices market.
Request For Sample Copy of Research Report at https://www.coherentmarketinsights.com/insight/request-sample/1771 Laser Resurfacing Devices Market – Dynamics The laser resurfacing devices market growth is projected to increase over the forecast period, owing to rising number of cosmetic procedures during the past decade. For instance, according to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, people in the U.S. spent over 15 billion dollars on combined surgical and nonsurgical procedures, in which nonsurgical procedures accounted for around 44%. The development and innovations in laser resurfacing devices allows faster healing, minimizes the time required for the procedure, and reduces the side effects, thereby driving growth of the market. Moreover, lower cost of these devices in comparison with surgeries and approval of laser devices by the U.S FDA for the treatment have propelled growth of the laser resurfacing devices market size. Laser Resurfacing Devices Market – Regional Insights On the basis of region, the global laser resurfacing devices market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America holds dominant position in the market, owing to rising adoption of technologically advanced devices and presence of major market players in this region, especially in the U.S. For instance, 2018 InMode Aesthetic Solutions, introduces EmbraceRF, a new facial contouring approach. Laser Resurfacing Devices Market – Competitive Landscape Key players operating in the global laser resurfacing devices market include Lumenis Cynosure, Inc., Alma Lasers, Altair Instruments, Cutera, Lutronic Corporation, Lynton Lasers Ltd, Syneron Medical Ltd., Sciton, Inc., and Quanta Aesthetic Lasers USA. Market players are focused towards adopting strategies such as collaborations and providing technologically advanced products to sustain their presence in the market. For instance, in 2018, SkinCeuticals and The HydraFacial Company collaborated to create a professional resurfacing protocol. Laser Resurfacing Devices Market – Taxonomy On the basis of type, the global laser resurfacing devices market is segmented into:
On the basis of device, the global laser resurfacing devices market is segmented into:
On the basis of indication, the global laser resurfacing devices market is segmented into:
On the basis of end user, the global laser resurfacing devices market is segmented into:
On the basis of geography, the global laser resurfacing devices market is segmented into:
Else Place an Enquiry Before Purchase @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2214 Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected] https://www.coherentmarketinsights.com/phase-xs/ About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Phytochemical APIs are active chemical compounds extracted from plants with the help of semi-synthetic procedures and possess medicinal properties. Phytochemicals are divided into two categories such as primary and secondary constituents. Primary phytochemicals includes chlorophyll, proteins, sugar, and amino acids, while secondary constituents contain terpenoids and alkaloids. Phytochemical API plays an important role in pharmaceutical companies for the production of new drugs for curing various diseases.
Global Phytochemical API Market Drivers Increasing preferences of herbal medicines over allopathic drugs is expected to boost growth of the phytochemical API market. Moreover, increasing initiatives by pharmacognosy research to develop drugs containing natural chemical compounds is another factor to drive the phytochemical API market growth. For instance, in 2017, as per new research paper published in the Journal of Natural Compounds, International Cooperative Biodiversity Group discovered new chemical, Patentiflorin A, which is derived from willow-leaved Justicia. Patentiflorin A could inhibit the action of reverse transcriptase much more effectively than Azidothymidine (AZT). AZT is an antiretroviral medication used to prevent and treat HIV/AIDS. Patentiflorin A acts as a novel anti-HIV agent that can be used with current anti-HIV drugs to suppress the activity of HIV virus and prevent AIDS. However, availability of prominent allopathic drugs to cure disease conditions in lesser time interval than herbal drugs is expected to hinder the growth of phytochemical API market. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2492 Global Phytochemical API Market - Regional Analysis On the basis of region, the global phytochemical API market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Geographically, North America is expected to witness conducive growth for phytochemical API market, owing to increasing number of pipeline studies to develop medications containing active chemical compounds extracted from plants. For instance, in August 2018, University of Michigan initiated phase 2/phase 3 clinical trial for colchicine, to study the effect of postoperative treatment of colchicine in Fontan patients. Colchicine, an anti-inflammatory agent, is a toxic alkaloid and secondary metabolite extracted from plants of the genus Colchicum. The study is estimated to complete by June 2020. Moreover, keys player in Europe are focused on adopting business strategies such as acquisitions and collaborations in order to strengthen its business, which is expected to show significant growth for phytochemical API market in the region. For instance, in 2014, Centroflora CMS, Luxembourg-based pharmaceutical group, acquired phytochemical API product portfolio from Boehringer Ingelheim. The company signed a multi-year exclusive agreement with Boehringer Ingelheim to supply phytochemical APIs products in the market. The acquired product portfolio includes chemical compounds such as atropine and atropine sulfate, digoxin, and digoxin micron, along with metildigoxin, homatropine methylbromide, homatropine hydrobromide, and dihydroergotamine mesylate. Key players for phytochemical API market include Kothari Phytochemicals & Industries Ltd., Lipo Foods, Medipure Pharmaceuticals Inc., Centroflora CMS, SeQuent Scientific Limited, Arboris LLC, Cargill Inc., Indo Phytochem Pharmaceuticals., and BASF SE. Click To Reading More On Global Phytochemical API Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] Bio-engineered stent plays a major role in modern healthcare as it expands the blood vessel to prevent a blockage of arteries in cardiovascular diseases such as coronary heart disease and ischemic heart disease.
The global bio-engineered stent market size was valued at US$ 2,764.2 million in 2017, and is projected to exhibit a CAGR of 8.7% over the forec ast period (2018 – 2026). Bio-engineered stent is used in treating blockage of coronary and peripheral artery, which is related to coronary heart disease, ischemic heart disease, and other cardiovascular diseases. High prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel demand for bio-engineered stent, which in turn is expected to drive the market growth. According to American Heart Association, in 2018, around 92.1 million people in the U.S. were suffering with some form of cardiovascular diseases or the after-effects of stroke. Moreover, around 836,546 deaths in the U.S. were due to cardiovascular diseases, which accounted for 1 in every 3 deaths in the country. Direct and indirect costs in the treatment of cardiovascular diseases and stroke in the country were estimated to be around US$ 329.7 billion in 2018, which includes both health expenditures and lost productivity. Major players operating in the global bio-engineered stent market include, Medtronic, plc., Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, Stentys Sao, Meril Life Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore and Associates, C. R. Bard, Endologix, Inc., Lombard Medical Technologies, Translumina GmbH, and JOTEC GmbH. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/2484 Similarly, according to World Health Organization (WHO), 2015, cardiovascular diseases are the highest cause of morbidity and mortality worldwide, with around 17.7 million cases representing 31% of all worldwide deaths in 2015, of which around 6.7 million were due to stroke and 7.4 million were due to coronary heart disease. However, availability of alternatives for the treatment of cardiac diseases, product recalls and failure, and stringent regulations for product approvals are expected to hinder the market growth. For instance in November 2017, Abbott recall Class 1 Device Recall Absorb Bioresorbable Vascular Scaffold (BVS) System, a absorbable coronary drug-eluting stent due to elevated rates of major adverse events, specifically, myocardial infraction and scaffold thrombosis when compared to patients treated with the Xience metallic drug eluting stent. North America holds a dominant position in the global bio-engineered stent market, owing to rapid growth in geriatric population, increasing incidences of cardiac ailments, coronary and peripheral artery diseases, and high prevalence of obesity in the region. According to World Population Prospects, the number of people aged 80 or over is projected to triple by 2050, from 137 million in 2017 to 425 million in 2050 in the U.S. This age bracket is expected to more than double worldwide, increasing from 962 million in 2017 to 2.1 billion in 2050. Moreover, key players in the market are focused on receiving regulatory approvals for novel products to reduce the burden of blood stream infections associated with bio-engineered stents. For instance, in September 2018, Biotronik SE & Co. KG received the U.S. Food and Drug Administration (FDA) approval for PK Papyrus covered coronary stent system for the treatment of acute coronary artery. Click To Reading More On Bio-engineered Stent Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] 2/27/2019 Blepharitis Treatment Market Advance Modifications In Treatment And Outlook Till 2026Read NowBlepharitis is a chronic condition that causes inflammation of the eyelids. Blepharitis usually affects the part of eyelid where eyelashes grow and occurs when tiny oil glands near this area are clogged, in turn causing irritation and redness of the eyes. Symptoms of blepharitis include high sensitivity to light, loss of eyelashes, watery eyes, burning sensation in the eyes, greasy eyelids, itchy eyes, red and swollen eyes, flaking of skin around the eyes, crusted eyelashes after waking up, more frequent blinking, abnormal growth of eyelashes, and stinging sensation in the eyes. Blepharitis causes seborrheic dermatitis, which is dandruff of the eyebrows and scalp, bacterial infection, clogged oil glands, malfunctioning of oil glands, rosacea. It also causes allergic reactions to eye medications, contact lens solutions or eye make-up and eyelash lice or mites.
Ask For In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1761 Blepharitis Treatment Market Drivers:- The blepharitis treatment market is expected to witness significant grow due to growing prevalence of ophthalmic disorders among the geriatric population. According to a survey conducted by American Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. It also states that blepharitis is observed in 37% male ophthalmic patients and 47% in female ophthalmic patients. Blepharitis market is also expected to grow due to increasing number of drugs in the pipeline. For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305 treats patients with early symptoms of blepharitis. Furthermore, new product launches and mergers and acquisitions over the recent past also contributes to market growth. For instance, in 2015, BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains hygiene. According to a study conducted by American Academy of Ophthalmology in 2015 around 50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this device helps prevent recurrence of blephairis and the treatment is pain-free. Blepharitis Treatment Market Regional Analysis:- North America Blepharitis treatment market is expected to hold dominant position due to increasing geriatric population, launch of new products, and increasing number of ophthalmic patients in the region. According to a survey conducted in the U.S., by Population Reference Bureau in 2016, states that the aging population increased by 24% as compared to 15% in 2014. Europe is expected to witness rapid growth due to new product launches of blepharitis drugs in the region. For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of natural tear film, restores moisture to the eye and also the surrounding area, as well as improves tear film lipid quality. Blepharitis Treatment Market Key Players:- Key players operating in the Blepharitis treatment market include Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite Vision Incorporated, Merck & Co, and Novartis AG Blepharitis Treatment Market Taxonomy:- The global Blepharitis treatment market is segmented based on disease type, treatment type, distribution channel, and region. By Disease Type:-
Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/blepharitis-treatment-market-1761 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] 2/27/2019 Laboratory Centrifuge Equipment Market 2018 | Industry Structure And Development 2026Read NowLaboratory centrifuge is an equipment used to separate different material from liquid medium based on their density, shape, size, and viscosity of liquid medium in which they are dissolved. Centrifuge equipment works on the principle of centrifugation, in which denser material settles at the bottom of a centrifuge tube. Centrifuge is used in various applications such as separation of cellular element such as RBC and WBC from blood sample, In hematology lab for Packed Cell Volume determination (Diagnostic Purpose majorly), removal of cellular component for microscopic study (Research Purpose), removal of protein precipitate from analytical sample, isolation of macromolecules such as DNA, RNA, and lipids from cell, and separation of solid or semisolid precipitant from analytical sample or two immiscible fluids from each other in suspension (Research Purpose). Increasing demand for multifunction, reliable and durable laboratory centrifuge equipment to conduct variety of laboratory work as mentioned above is driving growth of the laboratory centrifuge equipment market.
Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1231 Increasing diagnostics and research and development activities to fuel the growth of laboratory centrifuge equipment market According to the World Health Organization (WHO) fact sheet, in 2017, 70% of deaths worldwide were due to non-communicable disease (NCD) such as cardio-vascular disease, cancer, diabetes, which is influencing pharmaceutical companies to invest more in research and development of cost-effective therapies, ultimately increasing demand for essential lab equipment such as centrifuge. According to World Economic Forum 2015 statistics, pharmaceutical companies invest majorly on research and development (Astra Zeneca tops the list with investment of 25.5% of its total revenue of financial year 2014-15). Increasing health awareness among population is propelling the growth of diagnostic market for which laboratory centrifuge equipment is essential. North America region is leading the centrifuge equipment market. According to Organization for Economic Co-operation and Development (OECD) report, North America spends 2.5% more than rest of OECD countries on health in which diagnostics holds a major share. The recent past has witnessed a significant increase in number of clinical trials for generic products (Bioequivalence safety and efficacy) due to off patenting of novel drug molecules, which in turn is increasing the demand for centrifuge equipment. There is a very positive environment even at supranational union level where group of countries coming together to achieve common development goals like health through collaborative efforts e.g. United Nations has declared Healthy lives and promoting well-being for all at all ages as its Sustainable development goal no. 3 which nations has committed to achieved by 2030 through their individual effort. Major Players Major players in the global laboratory centrifuge equipment market include Thermo Fisher Scientific, Eppendorf Corporation, Beckmann Coulter Inc., Hettich Lab Technology, Danaher Corporation, Hitachi Koki ltd., and Bio-Rad Laboratories. Laboratory Centrifuge Equipment Market Taxonomy: On the basis of rotor design: • Fixed Angle Rotor • Horizontal Rotor • Vertical Rotor On the basis of application area: • Diagnostics • Research and Development On the basis configuration: • Bench Top • Portable • Micro centrifuge • Ultracentrifuge On the basis of temperature variation facility: • Refrigerated • Non-Refrigerated On the basis of speed of rotation: • Low • High • Ultra On the basis end user: • Diagnostic laboratories • Pharmaceutical and Biotech companies • Research and academic places Ask for Discount Before Purchase @ https://www.coherentmarketinsights.com/insight/request-discount/1231 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] An implantable bioartificial kidney is similar to existing extracorporeal renal assist device (RAD), which is a bioartificial kidney that combines a membrane hemofilter and a bioreactor to function as a healthy kidney. However, to work as a natural kidney, the bioartificial kidney should have high efficiency ultrafiltration membranes, should be able to regulate blood flow, and stabilize necessary cells. Implantable bioartificial kidney is capable of replicating the work of real kidney and can eliminate the need for dialysis. Implantable bioartificial kidney avoids constant physician oversight and need to take immunosuppressant drugs and medication.
Get In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2339 Implantable Bioartificial Kidney Market: Drivers Increasing number of chronic kidney disease patients, rising number of kidney failure incidences, and long waiting list for kidney transplants is expected to boost the global implantable bioartificial kidney market growth over the forecast period. For instance, according to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. Moreover, according to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease. These factors are expected to drive the global implantable bioartificial kidney market growth over the forecast period. Individual government organizations and manufacturers are working towards increasing the awareness of kidney diseases. For instance, American Kidney Fund (AKF) launched a comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). Moreover, The Kidney Project is a national research project, which aims to create a small, surgically implanted, and free-standing bioartificial kidney to treat end stage renal disease (ESRD). This kidney is expected to provide ESRD patients with a new option beyond the short-term solution of renal dialysis and the costly kidney transplant for which donor organs are limited. Implantable Bioartificial Kidney Market: Regional Analysis North America implantable bioartificial kidney market is expected to hold dominant position in the global market over the forecast period. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), over 661,000 people in the U.S. had kidney failure and of these, 468,000 individuals were on dialysis, in 2017. The kidney project, headed by researchers from the University of California San Francisco (UCSF), the University of Vanderbilt, and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), is expected to receive approval for the artificial kidney trials by late 2018 or early 2019. These factors are expected to support the North America implantable bioartificial kidney market growth over the forecast period. According to report of Brazilian Transplant Registry, 2016, Brazil accounts for the second largest number of kidney transplant programs in the world. Implantable Bioartificial Kidney Market: Taxonomy The global implantable bioartificial kidney market is segmented on the basis of end user, and region. By End User: Hospitals, Organ Transplant Centers, Others By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa Request For Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/2339 Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected] https://www.coherentmarketinsights.com/phase-xs/ About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Deafness is a result of an impairment in the ear or damage to the nerves associated with hearing. The causes for these defect include congenital defects, injuries, diseases, side effects of medications, age-related factors, and exposure to loud noise. Audiology devices are assistive tools that help enhance hearing ability of patients. These devices vary on the basis of size, shape, features, and hearing conditions. These devices are aimed towards diagnostic purposes as well as for the treatment of impairments associated with hearing. Advancements in technology related to these devices such as PC-based audiometers and hybrid audiometers can easily be integrated with standard computers and operating systems, resulting in improved diagnostic performance and treatment decisions. This in turn, is expected to boost growth of the global audiology devices market in the near future.
Rising incidence of hearing impairments is expected to drive market growth The audiology devices market holds a vast commercial base, as all the age groups varying from children to geriatric people can be affected by hearing problems. According to National Institute on Deafness and Other Communication Disorders (NIDCD), December 2016, around 2-3 in every 1,000 children in the U.S. suffered from an in-born detectable level of hearing loss in either one or both ears. Moreover, according to the reports of Hearing Loss Association of America (HLAA), 2017, around 20% of the population in the U.S., accounting for 48 million people are estimated to be suffering from some degree of hearing issues and hearing loss. As per statistical analysis conducted by World Health Organization (WHO), in 2016, hearing disorders affected around 360 million people around the globe, out of which, 32 million were children. Get HOLISTIC Request Sample Copy Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1008 Among devices, the cochlear implants segment is expected to witness maximum traction over the forecast period, as these implants serve to be an ideal substitute for hearing. Cochlear implant provides around 80% better understanding of a sentence, as compared conventional hearing aids that provide an average of 10% understanding. These implants use a technology that bypasses the impaired sensory hair cells, further presenting a virtual sense of sound. However, high costs associated with audiology devices, especially hearing implants are hampering growth of the audiology devices market. This creates greater opportunity for market players to develop cost-effective devices at affordable prices with longer shelf life. North America to dominate the global audiology devices market, owing to significant investments in research and development of innovate models North America is the leading geographical region in the global audiology devices market, owing to the presence of majority of key players as well as rampant development in audiology technology in the region. Asia Pacific is expected to witness maximum growth over the forecast period, owing to incorporation of various initiatives in the healthcare sector by regional government bodies and private organizations. For instance, World Wide Healing, a non-profit organization, provides hearing treatment to the poor in emerging economies of Asia. The organization provides new digital hearing aids shipped from manufacturers in North America and Europe. Furthermore, growing healthcare sector and growing awareness regarding hearing assistance among the populace is expected to favor growth of the audiology devices market in Asia Pacific. Key players operating the global audiology devices market include Widex A/S, Rayovac, Ambco, Benson Medical, Amplicomms, Tremetrix, Sonova Holdings AG, Starkey Hearing Technologies, Sophono, MED-EL, Advanced Bionics, AllHear, Cochlear Ltd., and Microson Hearing Aids. Regional players are developing innovative products to establish a strong foothold in the global market. For instance, Rayovac, a Europe based company debuted its active core technology for the first time offering longest durable high-quality battery in the hearing devices. Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1008 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] |
Details
Global Industry Research Experienced Professional Freelancer with a demonstrated history of working in the information technology and services industry. Skilled in Front Office, Customer Service, Marketing, Microsoft Office, and Social Media. Strong media and communication professional with a Bachelor of Commerce - BCom focused in Computer and Information Sciences and Support Services from Pune University. Archives
July 2020
Categories |